Retatrutide: Inside the Triple-Hormone Drug Reshaping Obesity and Diabetes Treatment

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are two of the toughest problems in medicine today, and they rarely travel alone: both feed into cardiovascular disease, chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), and a shorter life overall. Bariatric surgery has been the gold standard for effective weight loss for decades, but it's invasive, and there's simply no way it can scale to meet demand. That gap is what has pushed drug research toward mimicking the gut hormone changes surgery produces in the first place. Retatrutide (LY3437943) is the furthest that effort has been taken so far: a single molecule that activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors all at once. This review draws together the preclinical work, phase1 and 2 trials, emerging phase 3 data, and recent systematic reviews and meta-analyses to ask how retatrutide works, how well it performs, how safe it looks, and where it fits among the incretin-based therapies now reshaping this field. In phase 2 trials, the weight loss climbed with the dose: 24.2% at 48 weeks in people with obesity and 16.9% at 36 weeks in people with T2DM, ahead of every currently licensed obesity drug and edging toward what bariatric surgery has historically achieved. HbA1c fell by as much as 2.2%, and higher-dose participants reached near-normal glucose control. Liver fat dropped substantially (up to 86% in relative terms), blood pressure and lipids both improved, and there were early signs of kidney protection through reduced albuminuria. As with every drug in this class, the main tolerability issue is dose-related gastrointestinal side effects. A large phase 3 program is now underway across two parallel tracks, TRIUMPH for obesity and TRANSCEND-T2D for diabetes, using a basket-trial design that studies obstructive sleep apnea, knee osteoarthritis, cardiovascular disease, and CKD populations all at once. What they still don't know is how retatrutide affects long-term cardiovascular and renal outcomes, whether the weight loss holds after people stop treatment, how well lean mass is preserved, and how its cost will stack up against existing options. Retatrutide looks like a potentially transformative addition to obesity and T2DM care, but where it actually lands in practice will depend on what the ongoing phase 3 trials show.